S. Kralingen

The influence of morbid obesity on the pharmacokinetics and pharmacodynamics of drugs in adolescents and adults : focus on propofol and nadroparin

A. Rongen, S. Kralingen, 2013 .

Impact of Obesity on Drug Metabolism and Elimination in Adults and Children

C. Knibbe, J. Anker, J. Diepstraten, 2012, Clinical Pharmacokinetics.

Population Pharmacokinetics and Pharmacodynamics of Propofol in Morbidly Obese Patients

M. Danhof, M. Peeters, E. P. Dongen, 2011, Clinical pharmacokinetics.

Pharmacokinetics and protein binding of cefazolin in morbidly obese patients

M. Wiezer, E. P. Dongen, V. Deneer, 2011, European Journal of Clinical Pharmacology.

Treatment of Pulmonary Embolism in an Extremely Obese Patient

R. Snijder, C. Knibbe, C. Hackeng, 2009, Obesity surgery.

Level of agreement between cardiac output measurements using Nexfin® and thermodilution in morbidly obese patients undergoing laparoscopic surgery

C. Boer, P. Schraverus, M. M. Kuijpers, 2016, Anaesthesia.

Anti-Xa Levels 4 h After Subcutaneous Administration of 5,700 IU Nadroparin Strongly Correlate with Lean Body Weight in Morbidly Obese Patients

E. P. Dongen, C. Knibbe, C. Hackeng, 2012, Obesity Surgery.